The underutilisation of dual antiplatelet therapy in acute coronary syndrome.

[1]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[2]  G. Gamble,et al.  Survival after an acute coronary syndrome: 18‐month outcomes from the Australian and New Zealand SNAPSHOT ACS study , 2015, The Medical journal of Australia.

[3]  S. de Servi,et al.  Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. , 2015, European heart journal. Cardiovascular pharmacotherapy.

[4]  T. Jernberg,et al.  Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. , 2015, European heart journal.

[5]  I. Ranasinghe,et al.  Prescription of secondary prevention medications, lifestyle advice, and referral to rehabilitation among acute coronary syndrome inpatients: results from a large prospective audit in Australia and New Zealand , 2014, Heart.

[6]  C. Held,et al.  Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. , 2014, European heart journal.

[7]  C. Cannon,et al.  Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial , 2014, European heart journal.

[8]  C. Stefanadis,et al.  Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). , 2013, International journal of cardiology.

[9]  I. Ranasinghe,et al.  Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study , 2013, The Medical journal of Australia.

[10]  I. Ranasinghe,et al.  The design and rationale of the Australian Cooperative National Registry of Acute Coronary care, Guideline Adherence and Clinical Events (CONCORDANCE). , 2013, Heart, lung & circulation.

[11]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.

[12]  R. Califf,et al.  Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial , 2012, Circulation. Cardiovascular quality and outcomes.

[13]  J. Gore,et al.  Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. , 2011, The Canadian journal of cardiology.

[14]  C. Held,et al.  Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. , 2011, Circulation.

[15]  I. Ranasinghe,et al.  Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000–2007 , 2011, The Medical journal of Australia.

[16]  C. Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. , 2011, Journal of the American College of Cardiology.

[17]  K. Eagle,et al.  Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes , 2010, Heart.

[18]  L. Newby,et al.  Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. , 2009, American heart journal.

[19]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[20]  J. Gore,et al.  Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. , 2009, American heart journal.

[21]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[22]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.

[23]  R. Califf,et al.  Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. , 2006, Archives of internal medicine.

[24]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[25]  Deepak L. Bhatt,et al.  Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. , 2006, Archives of internal medicine.

[26]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[27]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[28]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[29]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[30]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[31]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[32]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.